ClinicalTrials.gg
RecruitingNCT05714124LEATUMUpdated Apr 12, 2024

Liver Embolization Approaches for Tumor Management

An observational study in Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Colon Cancer, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
580
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 206 studies in Carcinoma, Hepatocellular with a site in Italy — 49 open to participants now, 74 under way, 12 of them phase 3. Carcinoma, Hepatocellular · Italy.

Planned enrollment
17th of 60
580 · median 200
Started
2021
with 16 others
Observational
61 of 206
27 open now
Primary completion
2026-12
later than 36 of 73 live
Registered
153rd of 206
by date

Among the 206 studies in Carcinoma, Hepatocellular with a site in Italy, this one is the 17th largest by planned enrollment of the 60 observational ones that give a count, is one of 17 that started in 2021, is one of 61 observational ones, reaches primary completion later than 36 of the 73 other live ones, and was the 153rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

49 of the 206 studies in Carcinoma, Hepatocellular with a site in Italy are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Carcinoma, Hepatocellular with a site in Italy, or all of them as a file.
02

Study summary

The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Metastatic Colon Cancer
  • Metastatic Cancer
  • Metastatic Gastric Cancer
  • Primary Liver Cancer
  • Metastatic Pancreatic Cancer

Keywords

  • embolization, TAE, TACE, TARE, PVE, HVE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with primary or secondary liver tumors

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 yoa
  • patients with patients with primary or secondary liver disease not amenable for surgery or ablation
  • patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy
  • able and willing to sign

Exclusion criteria

Exclusion Criteria:

  • pregnant women
  • patients with uncorrectable coagulopathy
  • diffuse extrahepatic disease
  • for lobar TACE and TARE - presence of bilodigestive shunt
  • for TARE - >20% hepatopulmonary shunt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
580 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • ProcedureEmbolization

    Endovascular treatment for patients with primary and secondary liver tumors

    Also known as: Transarterial Chemoembolisation, Transarterial Radioembolization, Bland Transarterial Embolization, Hepatic Vein Embollization, Portal Vein Embolization

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Treatment Efficacy

    Time frame: Short term (3-6 months)

  2. Progression free survival

    Time frame: From time of intervention up to 1 year (medium term)

  3. Progression free survival

    Time frame: From time of intervention up to 5 years (Long term)

  4. Residual hepatic volume

    Treatment Efficacy

    Time frame: within 40 days of procedure

Secondary outcomes

  1. Overall survival

    Overall survival

    Time frame: From date of procedure until the date of death from any cause, whichever came first, assessed up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 6, 2023
StartActual
May 21, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2031
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05714124
Lead sponsor
IRCCS San Raffaele
Responsible party
Francesco De Cobelli (Head of Radiology, IRCCS San Raffaele) — Principal investigator
First posted
Feb 6, 2023
Start date
May 21, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Apr 12, 2024

Study contacts

Francesco De Cobelli, MD
Contact
trialcliniciradiologia@hsr.it
+39022643 ext. 2529
Stephanie Steidler, PhD
Contact
steidler.stephanie@hsr.it
+39022643 ext. 6111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion